{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:13:32Z","timestamp":1789391612236,"version":"build-2803163510"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,5,27]],"date-time":"2016-05-27T00:00:00Z","timestamp":1464307200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Romanian National Authority for Scientific Research and Innovation, CNCS \u2013 UEFISCDI","award":["PN-II-RU-TE-2014-4-2074"],"award-info":[{"award-number":["PN-II-RU-TE-2014-4-2074"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s12185-016-2020-4","type":"journal-article","created":{"date-parts":[[2016,5,27]],"date-time":"2016-05-27T11:09:54Z","timestamp":1464347394000},"page":"400-402","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Late relapsing mantle cell lymphoma showing preserved sensitivity to single-agent lenalidomide"],"prefix":"10.1007","volume":"104","author":[{"given":"Adrian","family":"Tempescul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Ianotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Bagacean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Yves","family":"Salaun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"Bocsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihnea","family":"Zdrenghea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,27]]},"reference":[{"key":"2020_CR1","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: WHO Press; 2008.","edition":"4"},{"key":"2020_CR2","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","volume":"34","author":"CY Cheah","year":"2016","unstructured":"Cheah CY, Seymour JF, Wang ML. Mantle cell lymphoma. J Clin Oncol. 2016;34:1256\u201369.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020_CR3","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00277-008-0692-4","volume":"88","author":"A Tempescul","year":"2009","unstructured":"Tempescul A, Ianotto JC, Morel F, Marion V, De Braekeleer M, Berthou C. Lenalidomide, as a single agent, induces complete remission in a refractory mantle cell lymphoma. Ann Hematol. 2009;88(9):921\u20132.","journal-title":"Ann Hematol"},{"issue":"8","key":"2020_CR4","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/ajh.24094","volume":"90","author":"JM Vose","year":"2015","unstructured":"Vose JM. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2015;90(8):739\u201345.","journal-title":"Am J Hematol"},{"issue":"11","key":"2020_CR5","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00277-012-1534-y","volume":"91","author":"M Witzens-Harig","year":"2012","unstructured":"Witzens-Harig M, Hess G, Atta J, Zaiss M, Lenz G, Scholz C, et al. Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting. Ann Hematol. 2012;91(11):1765\u201372.","journal-title":"Ann Hematol"},{"issue":"3","key":"2020_CR6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.blre.2014.10.001","volume":"29","author":"A Mussetti","year":"2015","unstructured":"Mussetti A, Kumar A, Dahi PB, Perales MA, Sauter CS. Lifting the mantle: unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma. Blood Rev. 2015;29(3):143\u201352.","journal-title":"Blood Rev"},{"issue":"17","key":"2020_CR7","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/1078-0432.CCR-15-0488","volume":"21","author":"I Avivi","year":"2015","unstructured":"Avivi I, Goy A. Refining the mantle cell lymphoma paradigm: impact of novel therapies on current practice. Clin Cancer Res. 2015;21(17):3853\u201361.","journal-title":"Clin Cancer Res"},{"key":"2020_CR8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/978-3-642-54490-3_21","volume":"201","author":"K Weisel","year":"2014","unstructured":"Weisel K, Kanz L. Lenalidomide. Recent Results Cancer Res. 2014;201:347\u201357.","journal-title":"Recent Results Cancer Res"},{"issue":"16","key":"2020_CR9","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood-2014-11-567792","volume":"125","author":"A Kritharis","year":"2015","unstructured":"Kritharis A, Coyle M, Sharma J, Evens AM. Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities. Blood. 2015;125(16):2471\u20136.","journal-title":"Blood"},{"issue":"3","key":"2020_CR10","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","volume":"145","author":"TM Habermann","year":"2009","unstructured":"Habermann TM, Lossos IS, Justice G, Vose JM, Wiernik PH, McBride K, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. 2009;145(3):344\u20139.","journal-title":"Br J Haematol"},{"issue":"7","key":"2020_CR11","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","volume":"22","author":"TE Witzig","year":"2011","unstructured":"Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin\u2019s lymphoma. Ann Oncol. 2011;22(7):1622\u20137.","journal-title":"Ann Oncol"},{"issue":"29","key":"2020_CR12","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","volume":"31","author":"A Goy","year":"2013","unstructured":"Goy A, Sinha R, Williams ME, Kalayoglu Besisik S, Drach J, Ramchandren R, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31(29):3688\u201395.","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-016-2020-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-016-2020-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-016-2020-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T05:11:31Z","timestamp":1559452291000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-016-2020-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,27]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["2020"],"URL":"https:\/\/doi.org\/10.1007\/s12185-016-2020-4","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,27]]}}}